Drug Pricing in the US

Boston, MA

ReportsWorldwide has announced the addition of a new report title Drug Pricing in the US to its growing collection of premium market research reports.

Drug prices in the US have been the subject of intense debate over the past 2–3 years, following a surge in spending on prescription medicines and steep price increases in some categories. Public support for government action to curb prices is widespread.

President Donald Trump has vowed to intervene, and the federal government is expected to unveil pricing reform proposals during the second half of 2017. In the meantime, state legislatures are debating a slew of bills designed to address prescription drug prices and curb pharmaceutical spending, while in the private sector, other stakeholders are keen to exert more control over a pricing agenda that is currently dominated by manufacturers and pharmacy benefit managers

For a Detailed description and table of contents of this report please click here: https://www.reportsworldwide.com/report/drug-pricing-in-the-us

Below are the key topics covered in this Report :

EXECUTIVE SUMMARY

• Paying the price for unrivaled access to prescription drugs
• Rebating has fueled a period of dramatic list price inflation
• Winners and losers under the current system
• Prospects for change

THE PRICING DEBATE RESURFACES

• A familiar problem that never went away
• Bibliography

PUBLIC SECTOR PRICES

• Not so free in practice
• Labyrinthine rules limit public purchasing and reimbursement prices
• The public sector drugs bill is still rising rapidly
• Bibliography

PRIVATE SECTOR PRICES

• Where market forces truly do run free
• PBMs – the pharmaceutical industry's main adversary
• PBM pressure has driven a rebating arms race
• Bibliography

THE REBATING BONANZA

• A solution, or part of the problem?
• List prices versus net prices: the gap becomes a gulf
• List price hikes have been used to create headroom for rebates
• Rebates soar, but net prices still comfortably outpace inflation
• Resetting the drug pricing debate
• Winners and losers under the current system
• Bibliography

DRUG PRICE REFORM PROSPECTS

• How might the drug pricing debate play out?
• Public support for pricing intervention is strong
• Public program prices and spending top the federal agenda
• Federal inaction prompts states to begin legislating on prices
• Market dynamics in the private sector begin to shift
• Seeking “value for money”
• Endgame scenarios
• Bibliography

APPENDIX

• About the author
• Scope
• Methodology

To Get Sample Copy of Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=41340

About ReportsWorldwide.com

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-1947
abigail@reportsworldwide.com

This release was published on openPR.